Person:

Mesirov, Jill

Loading...
Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Mesirov

First Name

Jill

Name

Mesirov, Jill

Search Results

Now showing 1 - 7 of 7
  • Publication

    Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers

    (Public Library of Science, 2013) Raeder, Maria B.; Birkeland, Even; Trovik, Jone; Krakstad, Camilla; Shehata, Shyemaa; Schumacher, Steven; Zack, Travis Ian; Krohn, Antje; Werner, Henrica MJ.; Moody, Susan E; Wik, Elisabeth; Stefansson, Ingunn M.; Holst, Frederik; Oyan, Anne M.; Tamayo, Pablo; Mesirov, Jill; Kalland, Karl H.; Akslen, Lars A.; Simon, Ronald; Beroukhim, Rameen; Salvesen, Helga B.

    Chromosome 8q24 is the most commonly amplified region across multiple cancer types, and the typical length of the amplification suggests that it may target additional genes to MYC. To explore the roles of the genes most frequently included in 8q24 amplifications, we analyzed the relation between copy number alterations and gene expression in three sets of endometrial cancers (N = 252); and in glioblastoma, ovarian, and breast cancers profiled by TCGA. Among the genes neighbouring MYC, expression of the bromodomain-containing gene ATAD2 was the most associated with amplification. Bromodomain-containing genes have been implicated as mediators of MYC transcriptional function, and indeed ATAD2 expression was more closely associated with expression of genes known to be upregulated by MYC than was MYC itself. Amplifications of 8q24, expression of genes downstream from MYC, and overexpression of ATAD2 predicted poor outcome and increased from primary to metastatic lesions. Knockdown of ATAD2 and MYC in seven endometrial and 21 breast cancer cell lines demonstrated that cell lines that were dependent on MYC also depended upon ATAD2. These same cell lines were also the most sensitive to the histone deacetylase (HDAC) inhibitor Trichostatin-A, consistent with prior studies identifying bromodomain-containing proteins as targets of inhibition by HDAC inhibitors. Our data indicate high ATAD2 expression is a marker of aggressive endometrial cancers, and suggest specific inhibitors of ATAD2 may have therapeutic utility in these and other MYC-dependent cancers.

  • Publication

    Transcriptional Profiling of Plasmodium falciparum Parasites from Patients with Severe Malaria Identifies Distinct Low vs. High Parasitemic Clusters

    (Public Library of Science, 2012) Milner, Danny; Pochet, Nathalie; Krupka, Malkie; Williams, Chris; Seydel, Karl; Taylor, Terrie E.; Van de Peer, Yves; Regev, Aviv; Wirth, Dyann; Daily, Johanna P.; Mesirov, Jill

    Background: In the past decade, estimates of malaria infections have dropped from 500 million to 225 million per year; likewise, mortality rates have dropped from 3 million to 791,000 per year. However, approximately 90% of these deaths continue to occur in sub-Saharan Africa, and 85% involve children less than 5 years of age. Malaria mortality in children generally results from one or more of the following clinical syndromes: severe anemia, acidosis, and cerebral malaria. Although much is known about the clinical and pathological manifestations of CM, insights into the biology of the malaria parasite, specifically transcription during this manifestation of severe infection, are lacking. Methods and Findings: We collected peripheral blood from children meeting the clinical case definition of cerebral malaria from a cohort in Malawi, examined the patients for the presence or absence of malaria retinopathy, and performed whole genome transcriptional profiling for Plasmodium falciparum using a custom designed Affymetrix array. We identified two distinct physiological states that showed highly significant association with the level of parasitemia. We compared both groups of Malawi expression profiles with our previously acquired ex vivo expression profiles of parasites derived from infected patients with mild disease; a large collection of in vitro Plasmodium falciparum life cycle gene expression profiles; and an extensively annotated compendium of expression data from Saccharomyces cerevisiae. The high parasitemia patient group demonstrated a unique biology with elevated expression of Hrd1, a member of endoplasmic reticulum-associated protein degradation system. Conclusions: The presence of a unique high parasitemia state may be indicative of the parasite biology of the clinically recognized hyperparasitemic severe disease syndrome.

  • Publication

    GenePattern flow cytometry suite

    (BioMed Central, 2013) Spidlen, Josef; Barsky, Aaron; Breuer, Karin; Carr, Peter; Nazaire, Marc-Danie; Hill, Barbara Allen; Qian, Yu; Liefeld, Ted; Reich, Michael; Mesirov, Jill; Wilkinson, Peter; Scheuermann, Richard H; Sekaly, Rafick-Pierre; Brinkman, Ryan R

    Background: Traditional flow cytometry data analysis is largely based on interactive and time consuming analysis of series two dimensional representations of up to 20 dimensional data. Recent technological advances have increased the amount of data generated by the technology and outpaced the development of data analysis approaches. While there are advanced tools available, including many R/BioConductor packages, these are only accessible programmatically and therefore out of reach for most experimentalists. GenePattern is a powerful genomic analysis platform with over 200 tools for analysis of gene expression, proteomics, and other data. A web-based interface provides easy access to these tools and allows the creation of automated analysis pipelines enabling reproducible research. Results: In order to bring advanced flow cytometry data analysis tools to experimentalists without programmatic skills, we developed the GenePattern Flow Cytometry Suite. It contains 34 open source GenePattern flow cytometry modules covering methods from basic processing of flow cytometry standard (i.e., FCS) files to advanced algorithms for automated identification of cell populations, normalization and quality assessment. Internally, these modules leverage from functionality developed in R/BioConductor. Using the GenePattern web-based interface, they can be connected to build analytical pipelines. Conclusions: GenePattern Flow Cytometry Suite brings advanced flow cytometry data analysis capabilities to users with minimal computer skills. Functionality previously available only to skilled bioinformaticians is now easily accessible from a web browser.

  • Publication

    Medulloblastoma Exome Sequencing Uncovers Subtype-Specific Somatic Mutations

    (2012) Pugh, Trevor J.; Weeraratne, Shyamal Dilhan; Archer, Tenley; Pomeranz Krummel, Daniel A.; Auclair, Daniel; Bochicchio, James; Carneiro, Mauricio O.; Carter, Scott L.; Cibulskis, Kristian; Erlich, R; Greulich, Heidi; Lawrence, Michael; Lennon, Niall; McKenna, Aaron; Meldrim, James; Ramos, Alex H.; Ross, Michael G.; Russ, Carsten; Shefler, Erica; Sivachenko, Andrey; Sogoloff, Brian; Stojanov, Petar; Tamayo, Pablo; Mesirov, Jill; Amani, Vladimir; Teider, Natalia; Sengupta, Soma; Francois, Jessica Pierre; Northcott, Paul A.; Taylor, Michael D.; Yu, Furong; Crabtree, Gerald R.; Kautzman, Amanda G.; Gabriel, Stacey B.; Getz, Gad; Jäger, Natalie; Jones, David T. W.; Lichter, Peter; Pfister, Stefan M.; Roberts, Thomas; Meyerson, Matthew; Pomeroy, Scott; Cho, Yoon-Jae

    Medulloblastomas are the most common malignant brain tumors in children1. Identifying and understanding the genetic events that drive these tumors is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others described distinct molecular subtypes of medulloblastoma based on transcriptional and copy number profiles2–5. Here, we utilized whole exome hybrid capture and deep sequencing to identify somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. Overall, medulloblastomas exhibit low mutation rates consistent with other pediatric tumors, with a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at statistically significant frequencies, including previously known mutated genes in medulloblastoma such as CTNNB1, PTCH1, MLL2, SMARCA4 and TP53. Recurrent somatic mutations were identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 mutations, and in the nuclear co-repressor (N-CoR) complex genes GPS2, BCOR, and LDB1, novel findings in medulloblastoma. We show that mutant DDX3X potentiates transactivation of a TCF promoter and enhances cell viability in combination with mutant but not wild type beta-catenin. Together, our study reveals the alteration of Wnt, Hedgehog, histone methyltransferase and now N-CoR pathways across medulloblastomas and within specific subtypes of this disease, and nominates the RNA helicase DDX3X as a component of pathogenic beta-catenin signaling in medulloblastoma.

  • Publication

    ISMB 2008 Toronto

    (Public Library of Science, 2008) Linial, Michal; Mesirov, Jill; Morrison McKay, B. J.; Rost, Burkhard

    The International Society for Computational Biology (ISCB) presents the Sixteenth International Conference on Intelligent Systems for Molecular Biology (ISMB 2008), to be held in Toronto, Canada, July 19–23, 2008. Now in the final phases of scheduling selected presentations, demonstrations, and posters, the organizers are preparing what will likely be recognized as the premier conference on computational biology in 2008. ISMB 2008 (http://www.iscb.org/ismb2008/) will follow the road paved by the ISMB/ ECCB 2007 (http://www.iscb.org/ ismbeccb2007/) in Vienna in the attempt to specifically encourage increased participation from previously under-represented disciplines of computational biology. This conference will feature the best of the computer and life sciences through a variety of core sessions running in multiple parallel tracks, along with single-tracked Keynote Presentations, posters on display throughout the duration of the conference, and an extensive commercial exposition. The first day (July 18) of the meeting is reserved for two-day Special Interest Group (SIG) and Satellite meetings, the second day (July 19) runs SIGs for the first time in parallel with Tutorials and the Student Council Symposium, and for the first time two SIGs are running in parallel with the main ISMB meeting (July 20–23)

  • Publication

    Portraits of breast cancer progression

    (BioMed Central, 2007) Dalgin, Gul S; Alexe, Gabriela; Scanfeld, Daniel; Tamayo, Pablo; Mesirov, Jill; Ganesan, Shridar; DeLisi, Charles; Bhanot, Gyan

    Background: Clustering analysis of microarray data is often criticized for giving ambiguous results because of sensitivity to data perturbation or clustering techniques used. In this paper, we describe a new method based on principal component analysis and ensemble consensus clustering that avoids these problems. Results: We illustrate the method on a public microarray dataset from 36 breast cancer patients of whom 31 were diagnosed with at least two of three pathological stages of disease (atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). Our method identifies an optimum set of genes and divides the samples into stable clusters which correlate with clinical classification into Luminal, Basal-like and Her2+ subtypes. Our analysis reveals a hierarchical portrait of breast cancer progression and identifies genes and pathways for each stage, grade and subtype. An intriguing observation is that the disease phenotype is distinguishable in ADH and progresses along distinct pathways for each subtype. The genetic signature for disease heterogeneity across subtypes is greater than the heterogeneity of progression from DCIS to IDC within a subtype, suggesting that the disease subtypes have distinct progression pathways. Our method identifies six disease subtype and one normal clusters. The first split separates the normal samples from the cancer samples. Next, the cancer cluster splits into low grade (pathological grades 1 and 2) and high grade (pathological grades 2 and 3) while the normal cluster is unchanged. Further, the low grade cluster splits into two subclusters and the high grade cluster into four. The final six disease clusters are mapped into one Luminal A, three Luminal B, one Basal-like and one Her2+. Conclusion: We confirm that the cancer phenotype can be identified in early stage because the genes altered in this stage progressively alter further as the disease progresses through DCIS into IDC. We identify six subtypes of disease which have distinct genetic signatures and remain separated in the clustering hierarchy. Our findings suggest that the heterogeneity of disease across subtypes is higher than the heterogeneity of the disease progression within a subtype, indicating that the subtypes are in fact distinct diseases.

  • Publication

    GeNets: A unified web platform for network-based analyses of genomic data

    Li, Taibo; Kim, April; Rosenbluh, Joseph; Horn, Heiko; Greenfeld, Liraz; An, David; Zimmer, Andrew; Liberzon, Arthur; Bistline, Jon; Natoli, Ted; Li, Yang; Tsherniak, Aviad; Narayan, Rajiv; Subramanian, Aravind; Liefeld, Ted; Wong, Bang; Thompson, Dawn; Calvo, Sarah; Carr, Steve; Boehm, Jesse; Jaffe, Jake; Mesirov, Jill; Hacohen, Nir; Regev, Aviv; Lage, Kasper